EichorEICHOR
Condition: Ros1 Positive Non Small Cell Lung Cancer Nsclc Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Ros1 Positive Non Small Cell Lung Cancer Nsclc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
Phase N/A · 1 location(s) · Centro de Tratamiento e Investigación sobre Cáncer, Luis Car · NCT07633626Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: RO
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT01639508Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Pingping Song · NCT05765877A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Xuanzhu Biopharmaceutical Co., Ltd. · NCT04996121Patient-centered, Optimal Integration of Survivorship and Palliative Care
NA · 1 location(s) · Massachusetts General Hospital · NCT04900935Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Phase 3 · 33 location(s) · Nuvation Bio Inc. · NCT07154706Study on the Mechanism of Acquired Resistance of Entrectinib
Phase N/A · 1 location(s) · Fudan University · NCT07199959REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis
Phase 2 · 16 location(s) · MedSIR · NCT06315010A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-smal
Phase 3 · 29 location(s) · Nuvation Bio Inc. · NCT06564324
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.